Eupraxia Pharmaceuticals (EPRX) Operating Expenses (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Operating Expenses data on file, last reported at $16.0 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 123.98% year-over-year to $16.0 million in Q1 2026; TTM through Mar 2026 was $47.3 million, a 72.29% increase from a year earlier, with the FY2025 full-year figure at $38.4 million, up 42.33% from the prior year.
• Operating Expenses for Q1 2026 stood at $16.0 million, down from $16.2 million in the prior quarter.
• Over the last five years, Operating Expenses for EPRX reached as high as $16.2 million in Q4 2025 and fell as low as $3.5 million in Q1 2023.
• Historically, Operating Expenses has averaged $8.4 million across 4 years, with a median of $6.9 million in 2025.
• Across the five-year window, Operating Expenses plunged 37.54% in 2024 and jumped 123.98% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $12.0 million in 2023, then sank by 37.54% to $7.5 million in 2024, then soared by 116.03% to $16.2 million in 2025, then fell by 1.27% to $16.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $16.0 million in Q1 2026, $16.2 million in Q4 2025, and $6.9 million in Q3 2025.